Kite, a Gilead Company, announced it has entered into a clinical trial collaboration with Pfizer on the development of a new treatment regimen for large B-cell lymphoma.
The clinical trial collaboration will evaluate the safety and efficacy of the investigational combination of Kite’s Yescarta and Pfizer's utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in patients with refractory large B-cell lymphoma.
The multi-center phase I/II study sponsored by Kite is expected to begin this year, with the results of this study to be used to evaluate options for further development of this combination, or similar combinations involving utomilumab and Kite therapies.
Read the press release
